Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 6Active not recruiting 4Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

pembrolizumab 68Cyclophosphamide 46Cisplatin 43Nivolumab 36Paclitaxel 33Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Bevacizumab 20Doxorubicin 19Magnetic Resonance Spectroscopy 18Blood Specimen Collection 18Radiosurgery 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Letrozole 15Ipilimumab 15Fluorouracil 15palbociclib 14Surveys and Questionnaires 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14durvalumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystoscopy × 90 days × Clear all
NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡